Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Abatacept Active Treatment1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 50
2Abatacept Delayed-Onset Treatment1件: Abatacept1件: D03203 2件: CD80,
CD86 💬		12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬1件: 50
3Active Investigational Treatment ENT-01----1件: 6
4Active Treatment Group 7% Hypertonic Saline----1件: 299
5Background Treatment----1件: 46
6Baricitinib treatment1件: Baricitinib1件: D10308 2件: JAK1,
JAK2 💬		35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 46
7Baseline Treatment----1件: 13
8BDMARD treatment----1件: 271
9Behavioral: CO-OP treatment protocol----1件: 6
10Behavioral: conservative treatment----1件: 291
11Behavioral: Tobacco Treatment Specialist (TTS) intervention1件: Tobacco leaf---1件: 299
12Best Medical Treatment----1件: 6
13Best médical treatment----1件: 6
14Bisphosphonate treatment----2件: 113, 299
15Botulism Toxin Treatment----1件: 161
16Break in L-carnitine treatment1件: Levocarnitine3件: D02030 ,
D02176 ,
D04713 		--1件: 316
17Chinese herbal medicine treatment----1件: 6
18Classic DMARDs treatment group----1件: 46
19Clobetasol Propionate cream treatment2件: Clobetasol,
Clobetasol propionate		2件: D01272 ,
D07715 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162
20Combination Product: Active treatment with dual therapy----1件: 2
21Corticosteroid treatment (Methylprednisolone or prednisolone)2件: Methylprednisolone,
Prednisolone		14件: D00407 ,
D00472 ,
D00751 ,
D00979 ,
D00980 ,
D00981 ,
D00982 ,
D01239 ,
D01998 ,
D02156 ,
D03301 ,
D05000 ,
D05001 ,
D05002 		1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 64
22Crysvita (burosumab-twza) Treatment1件: Burosumab1件: D10913 1件: FGF23 💬11件: Breast cancer, Calcium signaling pathway, Gastric cancer, MAPK signaling pathway, Melanoma, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton 💬1件: 238
23Current lipid-lowering treatment----1件: 79
24Current treatment of AL-CM----1件: 28
25Detoxifying agents for antineoplastic treatment----2件: 299, 337
26Disease modifying treatment (DMT)----1件: 13
27Dopamine agonist treatment1件: Dopamine2件: D00633 ,
D07870 		5件: DRD1,
DRD2,
DRD3,
DRD4,
DRD5 💬		11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬1件: 74
28Drug treatment----4件: 46, 51, 74, 271
29ERA as specific PAH treatment----1件: 86
30Etanercept Treatment1件: Etanercept1件: D00742 2件: LTA,
TNF 💬		67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 46
31Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 222
32Fibrate treatment----1件: 160
33Foliglurax 10 mg (treatment A)1件: Foliglurax---1件: 6
34Foliglurax 30 mg (treatment B)1件: Foliglurax---1件: 6
35From August 2020 'no additional treatment'----1件: 51
36GENOTROPIN (Somatropin) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference is that GENOTROPIN is man-made.1件: Somatotropin1件: D02691 1件: GHR 💬5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬1件: 193
37Glucocorticoid Treatment----1件: 41
38Golimumab treatment optimization.1件: Golimumab1件: D04358 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 97
39HCQ/CQ and CAB combined treatment----1件: 74
40Herbal treatment (SA100)----1件: 97
41Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment1件: Xenon2件: D01901 ,
D06339 		--1件: 85
42Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment1件: Xenon2件: D01901 ,
D06339 		--1件: 85
43Immunosuppressive treatment----1件: 66
44Immunosuppressive treatment (eg, rituximab)1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 64
45In double-blind phase: treatment with tofacitinib1件: Tofacitinib1件: D09970 4件: JAK1,
JAK2,
JAK3,
TYK2 💬		37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 107
46In open-label phase: treatment with tofacitinib1件: Tofacitinib1件: D09970 4件: JAK1,
JAK2,
JAK3,
TYK2 💬		37件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬1件: 107
47Interferon beta treatment to add-on atorvastatin treatment2件: Atorvastatin,
Human interferon beta		3件: D00258 ,
D00887 ,
D07474 		1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 13
48IV treatment with IGSC, 10%----1件: 65
49Lapaquistat acetate and current lipid-lowering treatment2件: Acetate,
Lapaquistat		---1件: 79
50Large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP5件: Dapsone,
Mycophenolate mofetil,
Mycophenolic acid,
Prednisolone,
Triamcinolone		18件: D00385 ,
D00472 ,
D00592 ,
D00752 ,
D00980 ,
D00981 ,
D00982 ,
D00983 ,
D00984 ,
D00985 ,
D01239 ,
D01998 ,
D02156 ,
D03301 ,
D05094 ,
D05095 ,
D05096 ,
D06216 		3件: IMPDH1,
IMPDH2,
NR3C1 💬		4件: Drug metabolism - other enzymes, Metabolic pathways, Neuroactive ligand-receptor interaction, Purine metabolism 💬1件: 162
51Lumacaftor-Ivacaftor treatment2件: Ivacaftor,
Lumacaftor		2件: D09916 ,
D10134 		1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
52Metformin treatment1件: Metformin2件: D00944 ,
D04966 		2件: PRKAA1,
PRKAA2 💬		20件: AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬1件: 46
53Methotrexate treatment1件: Methotrexate2件: D00142 ,
D02115 		2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬2件: 41, 46
54MK0812 / Duration of Treatment: 12 Weeks----1件: 46
55MSC treatment----1件: 49
56MSC treatment 01----1件: 96
57MSC treatment 02----1件: 96
58Natalizumab treatment1件: Natalizumab1件: D06886 1件: ITGA4 💬14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬1件: 13
59Nifurtimox-Eflronithine Combination Treatment (NECT)1件: Nifurtimox1件: D00833 --1件: 65
60Nusinersen Treatments1件: Nusinersen1件: D10881 1件: SMN2 💬-1件: 3
61OC oral solution treatment A----1件: 6
62OC oral solution treatment B----1件: 6
63OC oral solution treatment C----1件: 6
64OC oral solution treatment D----1件: 6
65Only 1 arm: treatment with MSC-AFP----1件: 96
66Optimized antiparkinsonian treatment----1件: 6
67Optimized oral treatment----1件: 6
68Oral anticoagulant treatment----1件: 86
69Other Parkinson's Disease treatments----1件: 6
70Other: Adalimumab treatment1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 151
71Other: Best Medical Treatment----1件: 6
72Other: Control wound treatment----1件: 36
73Other: Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)----1件: 96
74Other: current treatment----1件: 46
75Other: Dead Sea Solar and Water Treatment1件: Water1件: D00001 --1件: 46
76Other: Diet treatment----1件: 240
77Other: Intensify treatment with the existing drug----2件: 96, 97
78Other: Motor Assessments before taking regular PD treatment----1件: 6
79Other: Motor Assessments on regular PD treatment----1件: 6
80Other: Multidisciplinary intensive rehabilitation treatment----1件: 6
81Other: No active treatment----1件: 274
82Other: No anti-inflammatory treatment----1件: 271
83Other: No IT treatment----1件: 19
84Other: No treatment----2件: 53, 274
85Other: No Treatment Arm----1件: 13
86Other: No treatment given----1件: 78
87Other: Observation of Ocrelizumab as Treatment in RRMS Patients1件: Ocrelizumab1件: D05218 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13
88Other: On-demand treatment----1件: 299
89Other: Other: Symptomatic treatment of ALS----1件: 2
90Other: SLE treatment----1件: 49
91Other: Standard steroid treatment----1件: 113
92Other: Standard Treatment----1件: 227
93Other: Standard treatment according to the Clinical protocols----3件: 49, 51, 235
94Other: Usual drug treatment of Parkinson's disease----1件: 6
95Plasma from healthy young people treatment + Riluzole1件: Riluzole1件: D00775 14件: GRIA1,
GRIA2,
GRIA3,
GRIA4,
GRIK1,
GRIK2,
GRIK3,
GRIK4,
GRIK5,
GRIN1,
GRIN2A,
GRIN2B,
GRIN2C,
GRIN2D 💬		23件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 💬1件: 2
96PPI treatment----1件: 299
97Prednisone and ustekinumab treatment2件: Prednisone,
Ustekinumab		2件: D00473 ,
D09214 		4件: IL12A,
IL12B,
IL23A,
NR3C1 💬		29件: African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Neuroactive ligand-receptor interaction, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬1件: 41
98Prednisone treatment1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 41
99Probiotic treatment----1件: 294
100Propranolol treatment1件: Propranolol2件: D00483 ,
D08443 		3件: ADRB1,
ADRB2,
ADRB3 💬		12件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 227
101Regular treatment----1件: 97
102Repository Corticotropin Injection -Treatment Extension1件: Corticotropin1件: D00146 1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬1件: 84
103Routine Treatment of CD----1件: 96
104SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)----1件: 65
105SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)----1件: 65
106Simvastatin treatment for 28 days1件: Simvastatin1件: D00434 1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 299
107Standard of Care Treatment----3件: 53, 245, 246
108Standard Steroid Treatment----1件: 85
109Standard treatment with a conventional drug----1件: 13
110Standard-of-care treatment----1件: 49
111Standrd of Care treatment----1件: 64
112Study treatment PPI----1件: 166
113Surgery treatment----1件: 291
114Symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)3件: Aldosterone,
Angiotensin II,
Calcium (Synonym: Restoration Treatment)		3件: D00150 ,
D02014 ,
D10528 		3件: AGTR1,
AGTR2,
NR3C2 💬		17件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 222
115Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)4件: Azathioprine,
Mycophenolate mofetil,
Mycophenolic acid,
Tacrolimus		8件: D00107 ,
D00238 ,
D00752 ,
D03033 ,
D05094 ,
D05095 ,
D05096 ,
D08556 		7件: IMPDH1,
IMPDH2,
PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		36件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Drug metabolism - other enzymes, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 11
116Symptomatic Treatment, Steroids, Immunosuppressive Agents, Plasma Exchange(PE), Intravenous Immunoglobulin(IVIg)1件: Human immunoglobulin G---1件: 11
117Systemic non-biological treatments----2件: 46, 271
118The Comprehensive Treatment Regimen of Traditional Chinese Medicine----1件: 222
119The Standard Steroid Treatment, Plasma Exchange and rituximab1件: Rituximab1件: D02994 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 85
120Time delay treatment of botulinum toxin----1件: 149
121TL011, anti CD20, for the treatment of rheumatoid arthritis----1件: 46
122Tocilizumab treatment1件: Tocilizumab1件: D02596 1件: IL6R 💬12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬1件: 41
123Traditional treatment of CGD and TB----1件: 65
124Traditional treatments----1件: 97
125Transsphenoidal surgery treatment----1件: 74
126Treatment----2件: 41, 299
127Treatment A----2件: 34, 46
128Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status1件: Infliximab1件: D02598 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 96
129Treatment Algorithm A----1件: 97
130Treatment Algorithm B----1件: 97
131Treatment Algorithm C----1件: 97
132Treatment as Usual (TAU)----1件: 85
133Treatment B----2件: 34, 46
134Treatment BX1514M----1件: 58
135Treatment C----2件: 34, 46
136Treatment D----1件: 34
137Treatment defined only by active substance----1件: 50
138Treatment I----1件: 46
139Treatment II----1件: 46
140Treatment III----1件: 46
141Treatment intervention----1件: 61
142Treatment of MTX----1件: 46
143Treatment of MTX and HCQ----1件: 46
144Treatment of MTX and TwHF----1件: 46
145Treatment of TCM----1件: 46
146Treatment of TwHF----1件: 46
147Treatment Phase Group 4----1件: 113
148Treatment standard----1件: 61
149Treatment systemic therapy (prednisone)1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162
150Treatment with Adalimumab1件: Adalimumab1件: D02597 1件: TNF 💬67件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬1件: 96
151Treatment with azathioprin----1件: 95
152Treatment with cystic fibrosis transmembrane regulator (CFTR) modualtors Ivacaftor, Lumacaftor-Ivacaftor, Tezacaftor-Ivacaftor, Elexacaftor-Tezacaftor-Ivacaftor4件: Elexacaftor,
Ivacaftor,
Lumacaftor,
Tezacaftor		4件: D09916 ,
D10134 ,
D11041 ,
D11507 		1件: CFTR 💬8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬1件: 299
153Treatment with mycophenolat mofetil----1件: 95
154Treatment with polyethylene glycol (Macrogol 4000)1件: Polyethylene glycol1件: D03370 --1件: 299
155Treatment with systemic therapy (doxycycline)1件: Doxycycline5件: D00307 ,
D02129 ,
D03903 ,
D03904 ,
D07876 		--1件: 162
156Treatment with systemic therapy (methotrexate)1件: Methotrexate2件: D00142 ,
D02115 		2件: DHFR,
DHFR2 💬		5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬1件: 162
157Treatment with systemic therapy (prednisone)1件: Prednisone1件: D00473 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬1件: 162
158Treatment with topical superpotent corticosteroid therapy----1件: 162
159Untreated to atorvastatin treatment1件: Atorvastatin3件: D00258 ,
D00887 ,
D07474 		1件: HMGCR 💬4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬1件: 13
160Usual dopaminergic per os treatment----1件: 6
161Vancomycin Pre-Treatment1件: Vancomycin2件: D00212 ,
D00926 		--1件: 97
162Viral load driven treatment interruption----1件: 265